| Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence (NCT04763109) | Nicole Baca | 2022-07-08 |
| PASS of Paediatric Patients Initiating Selumetinib (NCT05388370) | AstraZeneca | 2022-05-23 |
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 (NCT05238909) | Ann & Robert H Lurie Children's Hospital of Chicago | 2022-03-04 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (NCT05309668) | AstraZeneca | 2022-01-21 |
| Molecular Aspects of Preimplantation Genetic Diagnosis for NF1 (NCT05149469) | University Hospital, Strasbourg, France | 2021-09-15 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas (NCT05101148) | AstraZeneca | 2021-07-21 |
| Natural History Study of Cutaneous Neurofibromas in People With NF1 (NCT05581511) | Johns Hopkins University | 2021-06-28 |
| Selumetinib Paediatric NF1 Japan Study (NCT04495127) | AstraZeneca | 2020-08-31 |
| Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis (NCT04153344) | Assistance Publique - Hôpitaux de Paris | 2020-05-11 |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma (NCT03871257) | National Cancer Institute (NCI) | 2020-01-15 |
| Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest (NCT05186870) | Guy's and St Thomas' NHS Foundation Trust | 2019-11-30 |
| Pediatric Long-Term Follow-up and Rollover Study (NCT03975829) | Novartis Pharmaceuticals | 2019-11-04 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (NCT03326388) | Great Ormond Street Hospital for Children NHS Foundation Trust | 2019-09-26 |
| Frameshift Peptides of Children With NF1 (NCT04212351) | Children's National Research Institute | 2019-04-11 |
| US Selumetinib Registry (NCT05683678) | Alexion Pharmaceuticals, Inc. | 2019-01-04 |
| Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation (NCT03757247) | Medical University Innsbruck | 2019-01-01 |
| Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia (NCT03190915) | National Cancer Institute (NCI) | 2018-09-09 |
| Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children (NCT03518710) | University Hospital, Toulouse | 2018-08-01 |
| FARD (RaDiCo Cohort) (RaDiCo-FARD) (NCT05954416) | Institut National de la Santé Et de la Recherche Médicale, France | 2018-03-07 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NCT03231306) | University of Alabama at Birmingham | 2017-11-28 |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma (NCT02839720) | National Cancer Institute (NCI) | 2017-08-26 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery (NCT02700230) | Mayo Clinic | 2017-03-22 |
| Interventions for Reading Disabilities in NF1 (NCT02964884) | Vanderbilt University | 2016-11-01 |
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. (NCT02777775) | Corewell Health West | 2016-05-01 |
| Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 (NCT02944032) | Kristina Hardy | 2016-05-01 |
| Stem Cells in NF1 Patients With Tumors of the Central Nervous System (NCT03332030) | Roger Packer | 2015-11-27 |
| Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients (NCT02505412) | Tel-Aviv Sourasky Medical Center | 2015-10-01 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (NCT02415153) | National Cancer Institute (NCI) | 2015-07-14 |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain (NCT02471339) | National Cancer Institute (NCI) | 2015-07-07 |
| Feasibility and Clinically Application of Magnetic Resonance Fingerprinting (NCT02387840) | Case Comprehensive Cancer Center | 2015-03-01 |
| Effect of Lamotrigine on Cognition in NF1 (NCT02256124) | Erasmus Medical Center | 2014-10-01 |
| Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. (NCT02078401) | Universitaire Ziekenhuizen KU Leuven | 2014-04-01 |
| Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 (NCT01851135) | Nantes University Hospital | 2013-05-01 |
| Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma (NCT02584413) | Washington University School of Medicine | 2013-04-16 |
| Neurofibromatosis Type 1 Brain Tumor Genetic Risk (NCT01707836) | Washington University School of Medicine | 2012-10-01 |
| Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma (NCT01553149) | National Cancer Institute (NCI) | 2012-07-05 |
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem (NCT01626846) | John Jay High School | 2012-06-01 |
| MicroRNAs in Patients With Neurofibromatosis Type 1 (NCT01595139) | Ann & Robert H Lurie Children's Hospital of Chicago | 2012-02-01 |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (NCT01362803) | National Cancer Institute (NCI) | 2011-09-21 |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (NCT01412892) | Assistance Publique - Hôpitaux de Paris | 2011-04-01 |
| Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs (NCT01218152) | KU Leuven | 2010-10-01 |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas (NCT01125046) | Northwestern University | 2010-06-17 |
| Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 (NCT01058330) | Shriners Hospitals for Children | 2010-02-01 |
| A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 (NCT00853580) | University of Alabama at Birmingham | 2009-07-01 |
| Reading Disability in Children With NF1 (NCT02397967) | University Hospital, Toulouse | 2009-06-01 |
| Functional Imaging and Reading Deficit in Children With NF1 (NCT02422732) | University Hospital, Toulouse | 2009-03-01 |
| Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I (NCT00684398) | National Human Genome Research Institute (NHGRI) | 2008-05-15 |
| A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (NCT00634270) | University of Alabama at Birmingham | 2008-04-01 |
| Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 (NCT00657202) | Massachusetts General Hospital | 2008-03-01 |
| Natural History Study of Patients With Neurofibromatosis Type I (NCT00924196) | National Cancer Institute (NCI) | 2008-02-25 |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients (NCT01218139) | KU Leuven | 2007-09-01 |
| Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments (NCT01445314) | National Cancer Institute (NCI) | 2007-03-23 |
| Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) (NCT00844129) | University of Utah | 2006-12-01 |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 (NCT00314119) | National Cancer Institute (NCI) | 2006-06-08 |
| Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma (NCT00352495) | Children's Oncology Group | 2006-06-01 |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine (NCT00326872) | National Cancer Institute (NCI) | 2006-05-01 |
| Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients (NCT00667836) | Shriners Hospitals for Children | 2006-03-01 |
| Neurobiology and Treatment of Reading Disability in NF-1 (NCT00624234) | Vanderbilt University | 2006-02-01 |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (NCT00304083) | Sarcoma Alliance for Research through Collaboration | 2005-12-01 |
| Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia (NCT00303368) | Shriners Hospitals for Children | 2004-03-01 |
| NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate (NCT00169611) | Hospices Civils de Lyon | 2004-01-01 |
| Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas (NCT00053937) | National Cancer Institute (NCI) | 2002-12-01 |
| Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma (NCT00060008) | Children's Hospital of Philadelphia | 2002-04-01 |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study (NCT00026780) | National Cancer Institute (NCI) | 2001-09-24 |
| Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas (NCT00030264) | Children's Hospital of Philadelphia | 2001-02-01 |